CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

2367  Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

2369  Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice
Bruce J. Giantonio
See related articles, p. 2394, 2400, 2408, 2416, 2424, and 2430

2372  Amplifying the Voice of the Whispering Cancer
Neesha C. Dhani
See related article, p. 2549

2375  New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma
Bradley A. McGregor and Guru P. Sonpavde
See related article, p. 2560

CCR Drug Updates

2378  FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Review

2383  IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy
Alvaro Teijeira, Saray Garasa, Maria C. Ochoa, Maria Villalba, Irene Olivera, Assunta Cirella, Inaki Eguren-Santamaria, Pedro Berraondo, Kurt A. Schalper, Carlos E. de Andrea, Miguel F. Sanmamed, and Ignacio Melero

Perspectives

2394  Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement
See related commentary, p. 2369

2400  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
See related commentary, p. 2369

2408  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group
See related commentary, p. 2369

2416  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group
Alexander I. Spira, Mark D. Stewart, Suzanne Jones, Elaine Chang, Anitra Fielding, Nicole Richie, Laura S. Wood, Michael A. Thompson, Lee Jones, Abhilasha Nair, Brandon A. Mahal, and David E. Gerber
See related commentary, p. 2369
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

See related commentary, p. 2369

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

See related commentary, p. 2369

CLINICAL TRIALS: IMMUNOTHERAPY

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy
# TABLE OF CONTENTS

## PRECISION MEDICINE AND IMAGING

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2505</td>
<td>The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer</td>
<td>Paolo Manca, Salvatore Corallo, Adele Busico, Sara Lonardi, Francesca Corti, Carlotta Antoniotti, Letizia Procaccio, Matteo Clavarezza, Valeria Smiroldo, Gianluca Tomaselblo, Roberto Murialdo, Andrea Sartore-Bianchi, Patrizia Racca, Filippo Pagani, Giovanni Randon, Antonia Martinetti, Elisa Sottotetti, Federica Palermo, Federica Perrone, Elena Tamborini, Michele Prisciandaro, Alessandra Pongelli, Maria Di Bartolomeo, Federica Morano, and Filippo Pietrantonio</td>
</tr>
<tr>
<td>2515</td>
<td>Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study</td>
<td>Yoshinori Kagawa, Elena Elez, Jesús García-Foncillas, Hideaki Bando, Hiroya Taniguchi, Ana Vivancos, Kiwamu Akagi, Ariadna García, Tadamichi Denda, Javier Ros, Tomohiro Nishina, Isoune Barcharab, Yoshito Komatsu, Davide Ciardiello, Eiji Oki, Toshihiro Kudo, Takeshi Kato, Takaharu Yamanaka, Josep Tabernero, and Takayuki Yoshino</td>
</tr>
<tr>
<td>2533</td>
<td>Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition</td>
<td>Hitendra S. Solanki, Eric A. Welsh, Bin Fang, Victoria Izumi, Lancia Darville, Brandon Stone, Ryan Franzese, Sandip Chavan, Fumi Kinose, Denis Imbody, John M. Koomen, Uwe Rix, and Eric B. Haura</td>
</tr>
</tbody>
</table>

## TRANSLATIONAL CANCER MECHANISMS AND THERAPY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2549</td>
<td>Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer</td>
<td>Lara Paracchini, Luca Beltrame, Tommaso Grassi, Alessia Inglesi, Robert Frusci, Fabio Landoni, Davide Ippolito, Martina Delle Marchette, Mariachiara Paderno, Marco Adorni, Marta Jaconi, Chiara Romualdi, Maurizio D’Incalci, Giulia Siravegna, and Sergio Marchini</td>
</tr>
<tr>
<td>2571</td>
<td>A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors</td>
<td>Fyza Y. Shaikh, James R. White, Joell J. Gills, Taiki Hakozaki, Corentin Richard, Bertrand Royut, Yusuke Okuma, Mykhaylo Usyk, Aboishek Pandey, Jeffrey S. Weber, Jeyoung Ahn, Evan J. Lipson, Jarushka Naidoo, Drew M. Pardall, and Cynthia L. Sears</td>
</tr>
</tbody>
</table>
2604  **KRAS**<sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
Gregory D. Jones, Raul Caso, Kay See Tan, Brooke Mastrogiamico, Francisco Sanchez-Vega, Yuan Liu, James G. Connolly, Yonina R. Murciano-Goroff, Matthew J. Bott, Prasad S. Adusumilli, Daniela Molenia, Gaetano Rocco, Valerie W. Rusch, Smita Sihag, Sandra Misale, Rona Yaeger, Alexander Drlon, Kathryn C. Arbour, Gregory J. Riely, Neal Rosen, Piro Lito, Haiying Zhang, David C. Lyden, Charles M. Rudin, David R. Jones, Bob T. Li, and James M. Isbell

2613  **Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas**
Amir Momeni-Boroujeni, Wissam Dahoud, Chad M. Vanderbilt, Sarah Chiang, Rajmohan Murali, Eric V. Rios-Doria, Kaled M. Alektiar, Carol Aghajanian, Nadeem R. Abu-Rustum, Marc Ladanyi, Lora H. Ellenson, Britta Weigelt, and Robert A. Soslow

2624  **G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma**

2636  **Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance**
Phillip M. Galbo Jr, Xingxing Zang, and Deyou Zheng

2648  **Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer**
Xian Wang, Jamunarani Veeraraghavan, Chia-Chia Liu, Xixi Cao, Lanfang Qin, Jin-Ah Kim, Ying Tan, Suet Kee Loo, Yi-leng Hu, Ling Lin, Sanghoon Lee, Martin J. Shea, Tamika Mitchell, Shunqiang Li, Matthew J. Ellis, Susan G. Hilsenbeck, Rachel Schiff, and Xiao-Song Wang

**CORRECTIONS**

2663  **Correction: A Virus-infected, Reprogrammed Somatic Cell-derived Tumor Cell (VIReST) Vaccination Regime can Prevent Initiation and Progression of Pancreatic Cancer**
Shuangshuang Lu, Zhe Zhang, Pan Du, Louisa K. Chard, Wenli Yan, Marqueritte El Khouri, Zhizhong Wang, Zhongxian Zhang, Yongchao Chu, Dongling Gao, Qinxian Zhang, Li-rong Zhang, Ai Nagano, Jun Wang, Claude Chelala, Jie Liu, Jiekai Chen, Pentao Liu, Yunshu Dong, Shengdian Wang, Xiaozhu Li, Jianzeng Dong, Nick R. Lemoine, Duanqing Pei, and Yaohe Wang

2664  **Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition**
Xin Chen, Ri-Xin Chen, Wen-Su Wei, Yong-Hong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gang-Jun Yuan, Si-Liang Chen, Sheng-Jie Guo, Kang-Hua Xiao, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, and Dan Xie

**EDITOR’S NOTES**

2665  **Editor’s Note: Epigenetic Modifications of RASSFIA Gene through Chromatin Remodeling in Prostate Cancer**
Ken Kawamoto, Steven T. Okino, Robert F. Place, Shinji Urakami, Hiroshi Hirata, Nobuyuki Kikuno, Toshifumi Kawakami, Yuichiro Tanaka, Deepa Pookot, Zhong Chen, Shahana Majid, Hideki Enokida, Masayuki Nakagawa, and Rajvir Dahiya
The cover shows an on-treatment biopsy taken from a patient with metastatic microsatellite stable colorectal cancer treated with combined PD-L1/CTLA-4 inhibition and targeted radiotherapy to a liver metastasis. Multiplex immunofluorescence staining demonstrates increased infiltration of CD8\(^{+}\)/(white)/PD-1\(^{+}\)/(green)/Ki-67\(^{+}\)/(red) cells with treatment. Cytokeratin (purple) highlights malignant cells. For details, see the article by Monjazeb and colleagues on page 2470 of this issue.